8-K: Salarius Pharma Rebrands as Decoy Therapeutics, Shifts Focus

Salarius Pharmaceuticals, Inc. has officially changed its corporate name to Decoy Therapeutics Inc. and its Nasdaq ticker symbol to DCOY, signaling a strategic pivot to next-generation peptide-conjugate therapeutics.

Summary

• Salarius Pharmaceuticals, Inc. has changed its legal name to Decoy Therapeutics Inc., effective January 8, 2026.
• The company's common stock will cease trading under the ticker symbol SLRX and begin trading under DCOY on the Nasdaq Capital Market, effective January 8, 2026.
• The name change reflects a strategic focus on developing novel peptide-conjugate therapeutics, initially targeting high-priority viral and oncology targets.
• The company is leveraging an AI-enabled discovery engine to accelerate candidate selection and reduce drug development complexity.
• A new corporate website, decoytx.com, will be launched effective January 8, 2026.

Sentiment

Score: 7

Explanation: The filing indicates a clear strategic pivot with a focus on advanced technology (AI, peptide conjugates) and a lead program that has attracted external interest. The rebranding and strategic clarity are positive, though the company remains preclinical with inherent risks.

Positives

• Clear strategic pivot to a focused area: next-generation peptide-conjugate therapeutics, with an initial emphasis on high-priority viral and oncology targets.
• Leveraging advanced technology with an AI-enabled discovery engine for speed and scale in drug discovery.
• Lead antiviral program has attracted strategic interest from the Biomedical Advanced Research and Development Authority (BARDA) and global health organizations, indicating potential for non-dilutive funding and partnerships.
• Existing financing from institutional investors and specific programs like the Massachusetts Life Sciences Seed Fund, Google AI startup program, and NVIDIA Inception program.
• Capital-efficient 2026 plan focused on advancing a lead antiviral into the clinic and expanding the pipeline.

Risks

• Risk that the company will not obtain sufficient financing to execute on its business plans.
• Risks related to Decoy's products and development plans, including unanticipated issues with any Investigational New Drug (IND) application process.
• The potential of the IMP3ACT platform may not be realized as expected.
• Risk that the company may not be able to maintain its listing on Nasdaq.
• Actual events or results may differ materially from forward-looking statements due to various factors.

Future Outlook

The company aims to advance its lead antiviral programs toward regulatory readiness, expand discovery and preclinical validation across multiple platforms, leverage AI-enabled computational infrastructure for candidate selection, and pursue strategic collaborations. This execution-focused approach is expected to achieve multiple value-creating milestones while retaining upside through partnerships and non-dilutive funding.

Management Comments

• "Changing our corporate name is another step in our transformation to developing the next generation of peptide-conjugate therapeutics, with an initial emphasis on high-priority viral and oncology targets." Rick Pierce, CEO of Decoy Therapeutics.
• "With an AI-enabled discovery engine, a lead antiviral program of interest to global health stakeholders and a tightly focused 2026 plan, we are positioned to advance our first program into the clinic, expand our pipeline and create long-term value for patients and shareholders." Rick Pierce, CEO of Decoy Therapeutics.

Industry Context

The rebranding and strategic shift align with a growing trend in the biotechnology sector towards specialized, platform-based drug discovery, particularly leveraging AI and machine learning to accelerate the identification and development of novel therapeutics. The focus on peptide-conjugate therapeutics and high-priority viral/oncology targets positions Decoy Therapeutics within a competitive but high-potential segment of the pharmaceutical industry, seeking to address significant unmet medical needs with potentially more efficient drug development pathways.

Corporate Governance

Stakeholder Impact

• Shareholders: Rights, total shares outstanding, CUSIP, and transfer agent are unaffected. Potential for long-term value creation through new strategic focus and milestones.
• Patients: Focus on developing novel therapeutics for high-priority viral and oncology targets aims to address unmet medical needs.
• Employees: Operations and leadership, including senior management and finance team, remain unchanged.
• Partners/Collaborators: New strategic focus and AI platform are designed to attract strategic collaborations and non-dilutive funding.

Next Steps

• Advance lead antiviral programs toward regulatory readiness.
• Expand discovery and preclinical validation across multiple platforms.
• Leverage AI-enabled computational infrastructure to accelerate candidate selection.
• Pursue strategic collaborations with big pharma, technology leaders, and academic institutions.
• Strengthen the company's capital structure and expand investor visibility.
• Support the filing of multiple investigational new drug (IND) applications and their enabling activities.
• Publish peer-reviewed publications.
• Engage in partnering discussions.

Key Dates

Recommendation

The rebranding and strategic pivot to AI-enabled peptide-conjugate therapeutics for viral and oncology targets present a clear, focused direction with potential for value creation. The company has attracted notable funding and strategic interest for its lead antiviral program. However, it remains a preclinical-stage biotechnology company, which inherently carries high risk and a long development timeline. While the strategic clarity is positive, the absence of immediate clinical data or significant near-term catalysts beyond preclinical advancement suggests a 'hold' for investors awaiting further progress and validation of the new strategy.

Keywords

Decoy Therapeutics, Salarius Pharmaceuticals, DCOY, SLRX, Peptide Conjugates, Biotechnology, Antiviral, Oncology, AI-enabled drug discovery, Nasdaq, Corporate Name Change, Ticker Symbol Change, BARDA, Preclinical